{"id":48635,"date":"2022-09-21T12:02:03","date_gmt":"2022-09-21T10:02:03","guid":{"rendered":"https:\/\/pharma-trend.com\/en\/igc-announces-issuance-of-second-patent-for-the-treatment-of-alzheimers-using-thc\/"},"modified":"2022-09-21T12:02:03","modified_gmt":"2022-09-21T10:02:03","slug":"igc-announces-issuance-of-second-patent-for-the-treatment-of-alzheimers-using-thc","status":"publish","type":"post","link":"https:\/\/pharma-trend.com\/en\/igc-announces-issuance-of-second-patent-for-the-treatment-of-alzheimers-using-thc\/","title":{"rendered":"IGC Announces Issuance of Second Patent for the Treatment of Alzheimer\u2019s Using THC"},"content":{"rendered":"<div>\n<p>POTOMAC, Md.&#8211;(BUSINESS WIRE)&#8211;<a href=\"https:\/\/twitter.com\/hashtag\/IGC?src=hash\" target=\"_blank\" rel=\"noopener\">#IGC<\/a>&#8211;India Globalization Capital, Inc. (\u201cIGC\u201d or the \u201cCompany\u201d) (NYSE American: IGC) announced today that the United States Patent and Trademark Office (\u201cUSPTO\u201d) issued a second patent (#11,446,276) for the treatment of Alzheimer\u2019s disease entitled \u201cExtreme low dose THC as a therapeutic and prophylactic agent for Alzheimer\u2019s disease.\u201d\n<\/p>\n<p><a href=\"https:\/\/mms.businesswire.com\/media\/20220921005448\/en\/772499\/5\/IGC_Logo.jpg\"><img decoding=\"async\" src=\"https:\/\/mms.businesswire.com\/media\/20220921005448\/en\/772499\/21\/IGC_Logo.jpg\"><\/a><\/p>\n<p>\nThe original patent application was initiated by the University of South Florida (\u201cUSF\u201d) and filed on July 30, 2015. On May 25, 2017, IGC entered into an exclusive license agreement with USF with respect to the patent application and the associated research conducted on Alzheimer\u2019s disease. On January 9, 2020, the patent application was modified by the Company. Separately, on July 22, 2021, IGC announced the grant of the first patent (11,065,225) for some of that research and work. This new patent is for a continuation of that work.\n<\/p>\n<p>\nThe Company\u2019s subsidiary, IGC Pharma, used some of the research to develop an oral formulation, IGC-AD1. Based on the USF research on Alzheimer\u2019s cell lines, subject to further testing and clinical trials, testing indicates that on a dose dependent manner, the active agents in IGC-AD1 may ameliorate A\u00df plaque and decrease <i>p<\/i>tau, a phosphorylated protein responsible for tangles in neurons. Plaques and tangles are key hallmarks of Alzheimer\u2019s disease. Further, testing in an Alzheimer\u2019s mouse model showed that it improved memory as demonstrated in a Morris Water Maze test.\n<\/p>\n<p>\nBased on these promising results, we initiated a Phase 1 study on safety and tolerability and in that study discovered that IGC-AD1 at specific dosing regimens had the potential to modify agitation and other neuropsychiatric symptoms in patients with Alzheimer\u2019s dementia. Encouraged by this, our short term focus shifted to further testing IGC-AD1 as a therapeutic for treating neuropsychiatric synmptoms in Alzheimer\u2019s, more specifically agitation. The Company recently filed a Phase 2 protocol with the U.S. Food and Drug Administration (\u201cFDA\u201d) for further clinical testing of the efficacy of IGC-AD1 on agitation in mild to severe Alzheimer\u2019s.\n<\/p>\n<p>\nCurrently, there are no FDA approved pharmacological treatments for agitation in dementia from Alzheimer\u2019s and about 70% of Alzheimer\u2019s patients suffer from agitation\/aggressiveness. The Company is hopeful that, subject to further trials and FDA approval, IGC-AD1 can provide relief for some of the over 55 million Alzheimer\u2019s patients worldwide.\n<\/p>\n<p>\n<b>About IGC:<\/b>\n<\/p>\n<p>\nIGC has two segments: Life Sciences and Infrastructure. The Company is based in Maryland, U.S.A.\n<\/p>\n<p>\n<b>Forward-looking Statements:<\/b> This press release contains forward-looking statements. These forward-looking statements are based largely on IGC\u2019s expectations and are subject to several risks and uncertainties, certain of which are beyond IGC\u2019s control. Actual results could differ materially from these forward-looking statements as a result of, among other factors, the Company\u2019s failure or inability to commercialize one or more of the Company\u2019s products or technologies, including the products or formulations described in this release, or failure to obtain regulatory approval for the products or formulations, where required; general economic conditions that are less favorable than expected, including as a result of the ongoing COVID-19 pandemic; the FDA\u2019s general position regarding cannabis- and hemp-based products; and other factors, many of which are discussed in IGC\u2019s SEC filings. IGC incorporates by reference the human trial disclosures and Risk Factors identified in its Annual Report on Form 10-K filed with the SEC on June 23, 2022, and Quarterly Report on Form10-Q, filed with SEC on August 5, 2022, as if fully incorporated and restated herein. In light of these risks and uncertainties, there can be no assurance that the forward-looking information contained in this release will occur.\n<\/p>\n<p> <b>Contacts<\/b> <\/p>\n<p>\nClaudia Grimaldi (301-983-0998)\n<\/p>\n<\/div>\n","protected":false},"excerpt":{"rendered":"<p>POTOMAC, Md.&#8211;(BUSINESS WIRE)&#8211;#IGC&#8211;India Globalization Capital, Inc. (\u201cIGC\u201d or the \u201cCompany\u201d) (NYSE American: IGC) announced today that the United States Patent and Trademark Office (\u201cUSPTO\u201d) issued a second patent (#11,446,276) for the treatment of Alzheimer\u2019s disease entitled \u201cExtreme low dose THC as a therapeutic and prophylactic agent for Alzheimer\u2019s disease.\u201d The original patent application was initiated &#8230; <span class=\"more\"><a class=\"more-link\" href=\"https:\/\/pharma-trend.com\/en\/igc-announces-issuance-of-second-patent-for-the-treatment-of-alzheimers-using-thc\/\">[Read more&#8230;]<\/a><\/span><\/p>\n","protected":false},"author":4,"featured_media":0,"comment_status":"closed","ping_status":"closed","sticky":false,"template":"","format":"standard","meta":{"footnotes":""},"categories":[13],"tags":[],"class_list":{"0":"entry","1":"post","2":"publish","3":"author-business","4":"post-48635","6":"format-standard","7":"category-industry"},"yoast_head":"<!-- This site is optimized with the Yoast SEO plugin v27.4 - https:\/\/yoast.com\/product\/yoast-seo-wordpress\/ -->\n<title>IGC Announces Issuance of Second Patent for the Treatment of Alzheimer\u2019s Using THC - Pharma Trend<\/title>\n<meta name=\"robots\" content=\"index, follow, max-snippet:-1, max-image-preview:large, max-video-preview:-1\" \/>\n<link rel=\"canonical\" href=\"https:\/\/pharma-trend.com\/en\/igc-announces-issuance-of-second-patent-for-the-treatment-of-alzheimers-using-thc\/\" \/>\n<meta property=\"og:locale\" content=\"en_US\" \/>\n<meta property=\"og:type\" content=\"article\" \/>\n<meta property=\"og:title\" content=\"IGC Announces Issuance of Second Patent for the Treatment of Alzheimer\u2019s Using THC - Pharma Trend\" \/>\n<meta property=\"og:description\" content=\"POTOMAC, Md.&#8211;(BUSINESS WIRE)&#8211;#IGC&#8211;India Globalization Capital, Inc. (\u201cIGC\u201d or the \u201cCompany\u201d) (NYSE American: IGC) announced today that the United States Patent and Trademark Office (\u201cUSPTO\u201d) issued a second patent (#11,446,276) for the treatment of Alzheimer\u2019s disease entitled \u201cExtreme low dose THC as a therapeutic and prophylactic agent for Alzheimer\u2019s disease.\u201d The original patent application was initiated ... [Read more...]\" \/>\n<meta property=\"og:url\" content=\"https:\/\/pharma-trend.com\/en\/igc-announces-issuance-of-second-patent-for-the-treatment-of-alzheimers-using-thc\/\" \/>\n<meta property=\"og:site_name\" content=\"Pharma Trend\" \/>\n<meta property=\"article:published_time\" content=\"2022-09-21T10:02:03+00:00\" \/>\n<meta property=\"og:image\" content=\"https:\/\/mms.businesswire.com\/media\/20220921005448\/en\/772499\/21\/IGC_Logo.jpg\" \/>\n<meta name=\"author\" content=\"Business Wire\" \/>\n<meta name=\"twitter:card\" content=\"summary_large_image\" \/>\n<meta name=\"twitter:label1\" content=\"Written by\" \/>\n\t<meta name=\"twitter:data1\" content=\"Business Wire\" \/>\n\t<meta name=\"twitter:label2\" content=\"Est. reading time\" \/>\n\t<meta name=\"twitter:data2\" content=\"3 minutes\" \/>\n<script type=\"application\/ld+json\" class=\"yoast-schema-graph\">{\"@context\":\"https:\\\/\\\/schema.org\",\"@graph\":[{\"@type\":\"Article\",\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/igc-announces-issuance-of-second-patent-for-the-treatment-of-alzheimers-using-thc\\\/#article\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/igc-announces-issuance-of-second-patent-for-the-treatment-of-alzheimers-using-thc\\\/\"},\"author\":{\"name\":\"Business Wire\",\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/#\\\/schema\\\/person\\\/02d41342c7a74fa7f0032bb35ef0bb24\"},\"headline\":\"IGC Announces Issuance of Second Patent for the Treatment of Alzheimer\u2019s Using THC\",\"datePublished\":\"2022-09-21T10:02:03+00:00\",\"mainEntityOfPage\":{\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/igc-announces-issuance-of-second-patent-for-the-treatment-of-alzheimers-using-thc\\\/\"},\"wordCount\":612,\"publisher\":{\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/#organization\"},\"image\":{\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/igc-announces-issuance-of-second-patent-for-the-treatment-of-alzheimers-using-thc\\\/#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/mms.businesswire.com\\\/media\\\/20220921005448\\\/en\\\/772499\\\/21\\\/IGC_Logo.jpg\",\"articleSection\":[\"Industry\"],\"inLanguage\":\"en-US\"},{\"@type\":\"WebPage\",\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/igc-announces-issuance-of-second-patent-for-the-treatment-of-alzheimers-using-thc\\\/\",\"url\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/igc-announces-issuance-of-second-patent-for-the-treatment-of-alzheimers-using-thc\\\/\",\"name\":\"IGC Announces Issuance of Second Patent for the Treatment of Alzheimer\u2019s Using THC - Pharma Trend\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/#website\"},\"primaryImageOfPage\":{\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/igc-announces-issuance-of-second-patent-for-the-treatment-of-alzheimers-using-thc\\\/#primaryimage\"},\"image\":{\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/igc-announces-issuance-of-second-patent-for-the-treatment-of-alzheimers-using-thc\\\/#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/mms.businesswire.com\\\/media\\\/20220921005448\\\/en\\\/772499\\\/21\\\/IGC_Logo.jpg\",\"datePublished\":\"2022-09-21T10:02:03+00:00\",\"breadcrumb\":{\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/igc-announces-issuance-of-second-patent-for-the-treatment-of-alzheimers-using-thc\\\/#breadcrumb\"},\"inLanguage\":\"en-US\",\"potentialAction\":[{\"@type\":\"ReadAction\",\"target\":[\"https:\\\/\\\/pharma-trend.com\\\/en\\\/igc-announces-issuance-of-second-patent-for-the-treatment-of-alzheimers-using-thc\\\/\"]}]},{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/igc-announces-issuance-of-second-patent-for-the-treatment-of-alzheimers-using-thc\\\/#primaryimage\",\"url\":\"https:\\\/\\\/mms.businesswire.com\\\/media\\\/20220921005448\\\/en\\\/772499\\\/21\\\/IGC_Logo.jpg\",\"contentUrl\":\"https:\\\/\\\/mms.businesswire.com\\\/media\\\/20220921005448\\\/en\\\/772499\\\/21\\\/IGC_Logo.jpg\"},{\"@type\":\"BreadcrumbList\",\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/igc-announces-issuance-of-second-patent-for-the-treatment-of-alzheimers-using-thc\\\/#breadcrumb\",\"itemListElement\":[{\"@type\":\"ListItem\",\"position\":1,\"name\":\"Startseite\",\"item\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/\"},{\"@type\":\"ListItem\",\"position\":2,\"name\":\"IGC Announces Issuance of Second Patent for the Treatment of Alzheimer\u2019s Using THC\"}]},{\"@type\":\"WebSite\",\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/#website\",\"url\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/\",\"name\":\"Pharma Trend\",\"description\":\"\",\"publisher\":{\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/#organization\"},\"potentialAction\":[{\"@type\":\"SearchAction\",\"target\":{\"@type\":\"EntryPoint\",\"urlTemplate\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/?s={search_term_string}\"},\"query-input\":{\"@type\":\"PropertyValueSpecification\",\"valueRequired\":true,\"valueName\":\"search_term_string\"}}],\"inLanguage\":\"en-US\"},{\"@type\":\"Organization\",\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/#organization\",\"name\":\"Pharma Trend\",\"url\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/\",\"logo\":{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/#\\\/schema\\\/logo\\\/image\\\/\",\"url\":\"\",\"contentUrl\":\"\",\"caption\":\"Pharma Trend\"},\"image\":{\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/#\\\/schema\\\/logo\\\/image\\\/\"}},{\"@type\":\"Person\",\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/#\\\/schema\\\/person\\\/02d41342c7a74fa7f0032bb35ef0bb24\",\"name\":\"Business Wire\"}]}<\/script>\n<!-- \/ Yoast SEO plugin. -->","yoast_head_json":{"title":"IGC Announces Issuance of Second Patent for the Treatment of Alzheimer\u2019s Using THC - Pharma Trend","robots":{"index":"index","follow":"follow","max-snippet":"max-snippet:-1","max-image-preview":"max-image-preview:large","max-video-preview":"max-video-preview:-1"},"canonical":"https:\/\/pharma-trend.com\/en\/igc-announces-issuance-of-second-patent-for-the-treatment-of-alzheimers-using-thc\/","og_locale":"en_US","og_type":"article","og_title":"IGC Announces Issuance of Second Patent for the Treatment of Alzheimer\u2019s Using THC - Pharma Trend","og_description":"POTOMAC, Md.&#8211;(BUSINESS WIRE)&#8211;#IGC&#8211;India Globalization Capital, Inc. (\u201cIGC\u201d or the \u201cCompany\u201d) (NYSE American: IGC) announced today that the United States Patent and Trademark Office (\u201cUSPTO\u201d) issued a second patent (#11,446,276) for the treatment of Alzheimer\u2019s disease entitled \u201cExtreme low dose THC as a therapeutic and prophylactic agent for Alzheimer\u2019s disease.\u201d The original patent application was initiated ... [Read more...]","og_url":"https:\/\/pharma-trend.com\/en\/igc-announces-issuance-of-second-patent-for-the-treatment-of-alzheimers-using-thc\/","og_site_name":"Pharma Trend","article_published_time":"2022-09-21T10:02:03+00:00","og_image":[{"url":"https:\/\/mms.businesswire.com\/media\/20220921005448\/en\/772499\/21\/IGC_Logo.jpg","type":"","width":"","height":""}],"author":"Business Wire","twitter_card":"summary_large_image","twitter_misc":{"Written by":"Business Wire","Est. reading time":"3 minutes"},"schema":{"@context":"https:\/\/schema.org","@graph":[{"@type":"Article","@id":"https:\/\/pharma-trend.com\/en\/igc-announces-issuance-of-second-patent-for-the-treatment-of-alzheimers-using-thc\/#article","isPartOf":{"@id":"https:\/\/pharma-trend.com\/en\/igc-announces-issuance-of-second-patent-for-the-treatment-of-alzheimers-using-thc\/"},"author":{"name":"Business Wire","@id":"https:\/\/pharma-trend.com\/en\/#\/schema\/person\/02d41342c7a74fa7f0032bb35ef0bb24"},"headline":"IGC Announces Issuance of Second Patent for the Treatment of Alzheimer\u2019s Using THC","datePublished":"2022-09-21T10:02:03+00:00","mainEntityOfPage":{"@id":"https:\/\/pharma-trend.com\/en\/igc-announces-issuance-of-second-patent-for-the-treatment-of-alzheimers-using-thc\/"},"wordCount":612,"publisher":{"@id":"https:\/\/pharma-trend.com\/en\/#organization"},"image":{"@id":"https:\/\/pharma-trend.com\/en\/igc-announces-issuance-of-second-patent-for-the-treatment-of-alzheimers-using-thc\/#primaryimage"},"thumbnailUrl":"https:\/\/mms.businesswire.com\/media\/20220921005448\/en\/772499\/21\/IGC_Logo.jpg","articleSection":["Industry"],"inLanguage":"en-US"},{"@type":"WebPage","@id":"https:\/\/pharma-trend.com\/en\/igc-announces-issuance-of-second-patent-for-the-treatment-of-alzheimers-using-thc\/","url":"https:\/\/pharma-trend.com\/en\/igc-announces-issuance-of-second-patent-for-the-treatment-of-alzheimers-using-thc\/","name":"IGC Announces Issuance of Second Patent for the Treatment of Alzheimer\u2019s Using THC - Pharma Trend","isPartOf":{"@id":"https:\/\/pharma-trend.com\/en\/#website"},"primaryImageOfPage":{"@id":"https:\/\/pharma-trend.com\/en\/igc-announces-issuance-of-second-patent-for-the-treatment-of-alzheimers-using-thc\/#primaryimage"},"image":{"@id":"https:\/\/pharma-trend.com\/en\/igc-announces-issuance-of-second-patent-for-the-treatment-of-alzheimers-using-thc\/#primaryimage"},"thumbnailUrl":"https:\/\/mms.businesswire.com\/media\/20220921005448\/en\/772499\/21\/IGC_Logo.jpg","datePublished":"2022-09-21T10:02:03+00:00","breadcrumb":{"@id":"https:\/\/pharma-trend.com\/en\/igc-announces-issuance-of-second-patent-for-the-treatment-of-alzheimers-using-thc\/#breadcrumb"},"inLanguage":"en-US","potentialAction":[{"@type":"ReadAction","target":["https:\/\/pharma-trend.com\/en\/igc-announces-issuance-of-second-patent-for-the-treatment-of-alzheimers-using-thc\/"]}]},{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/pharma-trend.com\/en\/igc-announces-issuance-of-second-patent-for-the-treatment-of-alzheimers-using-thc\/#primaryimage","url":"https:\/\/mms.businesswire.com\/media\/20220921005448\/en\/772499\/21\/IGC_Logo.jpg","contentUrl":"https:\/\/mms.businesswire.com\/media\/20220921005448\/en\/772499\/21\/IGC_Logo.jpg"},{"@type":"BreadcrumbList","@id":"https:\/\/pharma-trend.com\/en\/igc-announces-issuance-of-second-patent-for-the-treatment-of-alzheimers-using-thc\/#breadcrumb","itemListElement":[{"@type":"ListItem","position":1,"name":"Startseite","item":"https:\/\/pharma-trend.com\/en\/"},{"@type":"ListItem","position":2,"name":"IGC Announces Issuance of Second Patent for the Treatment of Alzheimer\u2019s Using THC"}]},{"@type":"WebSite","@id":"https:\/\/pharma-trend.com\/en\/#website","url":"https:\/\/pharma-trend.com\/en\/","name":"Pharma Trend","description":"","publisher":{"@id":"https:\/\/pharma-trend.com\/en\/#organization"},"potentialAction":[{"@type":"SearchAction","target":{"@type":"EntryPoint","urlTemplate":"https:\/\/pharma-trend.com\/en\/?s={search_term_string}"},"query-input":{"@type":"PropertyValueSpecification","valueRequired":true,"valueName":"search_term_string"}}],"inLanguage":"en-US"},{"@type":"Organization","@id":"https:\/\/pharma-trend.com\/en\/#organization","name":"Pharma Trend","url":"https:\/\/pharma-trend.com\/en\/","logo":{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/pharma-trend.com\/en\/#\/schema\/logo\/image\/","url":"","contentUrl":"","caption":"Pharma Trend"},"image":{"@id":"https:\/\/pharma-trend.com\/en\/#\/schema\/logo\/image\/"}},{"@type":"Person","@id":"https:\/\/pharma-trend.com\/en\/#\/schema\/person\/02d41342c7a74fa7f0032bb35ef0bb24","name":"Business Wire"}]}},"_links":{"self":[{"href":"https:\/\/pharma-trend.com\/en\/wp-json\/wp\/v2\/posts\/48635","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/pharma-trend.com\/en\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/pharma-trend.com\/en\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/pharma-trend.com\/en\/wp-json\/wp\/v2\/users\/4"}],"replies":[{"embeddable":true,"href":"https:\/\/pharma-trend.com\/en\/wp-json\/wp\/v2\/comments?post=48635"}],"version-history":[{"count":0,"href":"https:\/\/pharma-trend.com\/en\/wp-json\/wp\/v2\/posts\/48635\/revisions"}],"wp:attachment":[{"href":"https:\/\/pharma-trend.com\/en\/wp-json\/wp\/v2\/media?parent=48635"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/pharma-trend.com\/en\/wp-json\/wp\/v2\/categories?post=48635"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/pharma-trend.com\/en\/wp-json\/wp\/v2\/tags?post=48635"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}